Oral antihistamines provide little to no clinically relevant benefit for eczema symptoms, sleep disturbances, or overall disease severity in patients with atopic dermatitis, according to a systematic review and network meta-analysis published in the British Medical Journal. While the medications are widely used to manage itching, the findings indicate that older first-generation agents carry notable cognitive risks and higher rates of treatment discontinuation due to adverse effects.
Evaluating Antihistamines for Atopic Dermatitis
Atopic dermatitis is a chronic, recurring skin condition characterized by dry, inflamed, and intensely itchy skin. According to data cited by the Deutsche Apotheker Zeitung, about one in five patients in the United Kingdom and nearly one in two patients in the United States use oral antihistamines to manage the condition. Despite this widespread use, their therapeutic value has remained controversial. A 2019 Cochrane review previously found no consistent evidence supporting H1-antihistamines as an effective add-on therapy compared to a placebo.
To update these evaluations, researchers conducted a systematic review and network meta-analysis incorporating 47 randomized controlled trials, according to reporting by Aponet.de. The studies included a total of 6,230 children and adults presenting primarily with moderate-to-severe eczema. The meta-analysis compared standard eczema care with and without the addition of oral H1-antihistamines.
Limited Efficacy on Itching and Sleep
The analysis revealed that while H1-antihistamines slightly reduced eczema severity and itching scores, the observed difference was clinically insignificant for patients, as reported by Aponet.de. Furthermore, secondary symptoms such as sleep disturbances and acute disease flares did not meaningfully improve with the additional medication.
Safety data from the review highlighted specific drawbacks associated with older drug classes. Antihistamines belonging to the first generation frequently induced sedative effects, increasing risks for daytime drowsiness and reduced concentration. The analysis also noted that trial participants discontinued treatment more often when taking these older formulations because of adverse side effects.
Clinical Recommendations and Study Limitations
Although the systematic review ranks among the largest investigations into this treatment approach, the authors noted limitations regarding the varying quality of the included clinical trials, which restricts the certainty of conclusions for individual drug compounds. Nonetheless, the findings suggest that clinicians should avoid prescribing oral antihistamines as a routine component of atopic dermatitis management. Medical professionals emphasize that any adjustments to an eczema treatment regimen should be discussed directly with a treating physician.
Related reading